61.13
0.92 (1.53%)
| Previous Close | 60.21 |
| Open | 60.42 |
| Volume | 453,853 |
| Avg. Volume (3M) | 819,814 |
| Market Cap | 2,861,475,328 |
| Price / Earnings (TTM) | 16.84 |
| Price / Earnings (Forward) | 10.98 |
| Price / Sales | 2.18 |
| Price / Book | 3.05 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2026 |
| Profit Margin | 12.32% |
| Operating Margin (TTM) | 17.20% |
| Diluted EPS (TTM) | 3.31 |
| Quarterly Revenue Growth (YOY) | -3.70% |
| Quarterly Earnings Growth (YOY) | 184.70% |
| Total Debt/Equity (MRQ) | 156.35% |
| Current Ratio (MRQ) | 1.62 |
| Operating Cash Flow (TTM) | 181.72 M |
| Levered Free Cash Flow (TTM) | 183.89 M |
| Return on Assets (TTM) | 6.65% |
| Return on Equity (TTM) | 18.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | Haemonetics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.50 |
|
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 1.10% |
| % Held by Institutions | 118.44% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| North Peak Capital Management, Llc | 31 Dec 2025 | 1,102,992 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 94.00 (Barrington Research, 53.77%) | Buy |
| Median | 84.00 (37.41%) | |
| Low | 70.00 (Citigroup, 14.51%) | Hold |
| Average | 83.00 (35.78%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 59.66 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 11 Mar 2026 | 70.00 (14.51%) | Hold | 60.62 |
| 06 Feb 2026 | 75.00 (22.69%) | Hold | 59.34 | |
| BTIG | 06 Feb 2026 | 88.00 (43.96%) | Buy | 59.34 |
| Barrington Research | 06 Feb 2026 | 94.00 (53.77%) | Buy | 59.34 |
| 02 Feb 2026 | 93.00 (52.13%) | Buy | 65.78 | |
| Mizuho | 06 Feb 2026 | 80.00 (30.87%) | Buy | 59.34 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 05 Feb 2026 | Announcement | Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |